Citadel Advisors’s IGC Pharma IGC Stock Holding History

Citadel Advisors’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,800	Closed	-$3.63K	–	14978
2024 Q4	$3.63K	Sell	10,800 -7,900	-42%	-$2.96K	﹤0.01%	13985
2024 Q3	$7.98K	Hold	18,700	–	–	﹤0.01%	13327
2024 Q2	$8.11K	Buy	+18,700	New	+$9.3K	﹤0.01%	13211
2024 Q1	–	Sell	-10,800	Closed	-$3.02K	–	14981
2023 Q4	$3.02K	Hold	10,800	–	–	﹤0.01%	13636
2023 Q3	$3.88K	Hold	10,800	–	–	﹤0.01%	13539
2023 Q2	$3.37K	Hold	10,800	–	–	﹤0.01%	13699
2023 Q1	$3.67K	Sell	10,800 -101,500	-90%	-$38.1K	﹤0.01%	14021
2022 Q4	$35.7K	Sell	112,300 -26,300	-19%	-$10.7K	﹤0.01%	12540
2022 Q3	$60K	Buy	138,600 +5,400	+4%	+$2.88K	﹤0.01%	11499
2022 Q2	$71K	Buy	133,200 +15,400	+13%	+$9.71K	﹤0.01%	11693
2022 Q1	$112K	Hold	117,800	–	–	﹤0.01%	12165
2021 Q4	$115K	Sell	117,800 -65,200	-36%	-$87.5K	﹤0.01%	12574
2021 Q3	$271K	Sell	183,000 -29,400	-14%	-$47.5K	﹤0.01%	11278
2021 Q2	$348K	Buy	212,400 +500	+0.2%	+$763	﹤0.01%	10902
2021 Q1	$379K	Buy	211,900 +154,900	+272%	+$281K	﹤0.01%	10313
2020 Q4	$89K	Sell	57,000 -33,000	-37%	-$48.8K	﹤0.01%	10288
2020 Q3	$94K	Buy	+90,000	New	+$91.5K	﹤0.01%	9300

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors's IGC Position: Q2 2026 in Review

Citadel Advisors opened a new position in IGC Pharma (IGC) in Q2 2026: 437,317 shares worth $119K. The stake represents ﹤0.01% of the portfolio and ranks #12544 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IGC as recently as Q4 2025.

Citadel Advisors first reported a position in IGC in Q4 2013 and has held it in 31 quarters since. The position peaked at $262K in Q3 2025. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

Citadel Advisors held 437,317 shares of IGC Pharma worth $119K as of Q2 2026.
IGC Pharma was a new Citadel Advisors position in Q2 2026.
IGC Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12544 holding.
Citadel Advisors first reported a position in IGC Pharma in Q4 2013 and has held it in 31 quarters since.
Citadel Advisors's IGC Pharma position peaked at $262K in Q3 2025.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.